Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
NEUROCRINE BIOSCIENCES INC (NBIX)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/06/2023
8-K
Other Events Interactive Data
10/05/2023
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
"
08/01/2023
8-K
Quarterly results
07/13/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/11/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
BYLAW AMENDMENT
"
05/19/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
"
05/03/2023
8-K
Quarterly results
02/10/2023
8-K
Quarterly results
02/06/2023
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
"
01/09/2023
8-K
Entry into a Material Definitive Agreement Interactive Data
Docs:
"
Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases - Voyager to receive up-front consideration of $175 million including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in the U.S. for the GBA1 program following Phase 1 readout -
"
11/01/2022
8-K
Quarterly results
08/30/2022
8-K
Regulation FD Disclosure Interactive Data
08/04/2022
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance
"
05/31/2022
8-K
Quarterly results
05/24/2022
8-K
Quarterly results
05/23/2022
8-K
Quarterly results
05/04/2022
8-K
Quarterly results
02/11/2022
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
"
01/06/2022
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
"
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
"
12/23/2021
8-K
Other Events Interactive Data
11/22/2021
8-K
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data
Docs:
"
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
"
11/01/2021
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
"
08/03/2021
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
"
05/21/2021
8-K
Quarterly results
05/05/2021
8-K
Quarterly results
04/16/2021
8-K
Quarterly results
02/04/2021
8-K
Quarterly results
02/02/2021
8-K
Quarterly results
01/08/2021
8-K
Quarterly results
11/24/2020
8-K
Other Events Interactive Data
11/19/2020
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
Neurocrine Biosciences Announces Repurchase of Convertible Notes
"
11/09/2020
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Third Quarter 2020 Financial Results
"
09/10/2020
8-K
Investor presentation
Docs:
"
the 15th Annual Citi Biopharma Conference. I'm Neena Birtritto-Garg.
"
08/28/2020
8-K
Quarterly results
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy